Ginkgo Bioworks Holdings financials
$11.96+14.34%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $170.2M | $227.0M | $251.5M | $477.7M | $313.8M |
| Gross profit | $123.2M | $182.5M | $197.4M | $273.5M | $184.1M |
| Gross margin | 72.4% | 80.4% | 78.5% | 57.3% | 58.7% |
| Operating income | -$315.3M | -$559.8M | -$864.4M | -$2.17B | -$1.83B |
| Net income | -$312.8M | -$547.0M | -$892.9M | -$2.10B | -$1.83B |
| Net margin | −183.8% | −240.9% | −355.1% | −440.6% | −583.1% |
| Diluted EPS | $-5.64 | $-10.54 | $-18.37 | $-50.20 | $-55.60 |
| EBITDA | -$244.9M | -$424.7M | -$697.7M | -$2.15B | -$1.80B |
| Operating cash flow | -$171.1M | -$319.6M | -$295.5M | -$252.2M | -$253.8M |
| Free cash flow | -$178.7M | -$382.1M | -$336.3M | -$312.1M | -$310.3M |
| Diluted shares | 55.5M | 51.9M | 48.6M | 42.0M | 34.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $167.2M | $561.6M | $944.1M | $1.32B | $1.55B |
| Short-term investments | $255.4M | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $22.3M |
| Total assets | $1.12B | $1.38B | $1.67B | $2.54B | $2.07B |
| Total liabilities | $611.1M | $661.4M | $568.2M | $792.2M | $503.6M |
| Shareholders' equity | $508.6M | $716.1M | $1.10B | $1.75B | $1.57B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology